Daniel W. Sherbenou

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold et al. · The Lancet Haematology · 2019 · 249 citations · Full text

Hematological Malignancy, Oncology, Hematology +6

Characterization of Murine JAK2V617F-Positive Myeloproliferative Disease

Thomas G.P. Bumm, Collin Elsea, Amie S. Corbin et al. · Cancer Research · 2006 · 193 citations · Full text

Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Shaji Kumar, Natalie S. Callander, Kehinde Adekola et al. · Journal of the National Comprehensive Cancer Network · 2023 · 127 citations · Full text

Hematological Malignancy, Relapsed/refractory Mm, Medicine +15

Disruption of IRE1α through its kinase domain attenuates multiple myeloma

Jonathan M. Harnoss, Adrien Le Thomas, Anna Shemorry et al. · Proceedings of the National Academy of Sciences · 2019 · 112 citations · Full text

Combined Abl Inhibitor Therapy for Minimizing Drug Resistance in Chronic Myeloid Leukemia: Src/Abl Inhibitors Are Compatible with Imatinib

Thomas O’Hare, Denise K. Walters, Eric P. Stoffregen et al. · Clinical Cancer Research · 2005 · 102 citations